Skin cancer imaging vendor Michelson Diagnostics has announced plans to expand the availability of its VivoSight OCT optical coherence tomography (OCT) system in the U.S.
In support of the move, the U.K.-based company has opened a subsidiary office in Boston and named Karen Miller Gillis as general manager.
A multibeam OCT system, Vivo OCT is designed to aid dermatologists in evaluating the tissue microstructure of the skin in patients who are receiving treatment for nonmelanoma skin cancer, according to the vendor. The scanner can image up to 2 mm below the surface of a patient's skin, providing 2D, cross-sectional, real-time imaging of external tissues of the human body, Michelson said.
